

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease [Corrigendum]

Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. *Neuropsychiatr Dis Trea*. 2014;10:391–401.

“– Gal at stable dose (at least 18 mg/day) as achieved on day 84^c” should be “– Gal at stable dose (at least 16 mg/day) as achieved on day 84^c”. The correct figure is shown below.

On page 393, Figure 1, “Maintenance period (month 6 to 24)” should be “Maintenance period (month 4 to 24)”;

Pretreatment phase (day –28 to –1)

Baseline (day 0)

Treatment phase


Titration period (day 1 to 84)

- Gal 8 mg/day: day 1 to day 28
- Gal 16 mg/day: day 29 to day 56
- Gal up to 24 mg/day: day 57 to day 84^a
- Matching placebo

Maintenance period (month 4 to 24)

- Gal at stable dose (at least 16 mg/day) as achieved on day 84^c
- Matching placebo
- End-of-study/early withdrawal (month 24)

Posttreatment/follow-up (+1 month [month 25])



Notes: ^aUptitration (from 16 mg/day to 24 mg/day) or downtitration (from 24 mg/day to 16 mg/day) of dose was allowed, based on tolerability and the investigator's judgment. Patients unable to tolerate a minimum of 16 mg/day dose were to discontinue treatment and were followed until the end of the maintenance and posttreatment period. The total number of patients included in the safety analysis set was n=2,045; ^bearly study termination, per Data Safety Monitoring Board recommendation, when the prespecified number of deaths was ascertained and a significant imbalance favoring galantamine was observed; ^ca one-time dose titration to 16 or 24 mg/day was allowed, based on the investigator's judgment and patient tolerability.

Abbreviation: Gal, galantamine.

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS,

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.